![[117] Gabapentin and pregabalin: Are high doses justified?](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2019/02/117-150x150.png)
Analgesia once seemed a relatively straightforward aspect of medicine. Recommendations in textbooks and guidelines were definitive, albeit heavily conflicted. Even recent guidelines encourage dose titration, based on an implicit, if unsupported, … Read More
What’s New
![[Mar 27] Methods Speaker Series: Navigating the p-value swamp for meta-analysts](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2019/02/selfphoto3_closeup-132x150.png)
[Mar 27] Methods Speaker Series: Navigating the p-value swamp for meta-analysts
TI Methods Speaker Series WHEN: Wednesday, March 27th, 2019 from 12:00 noon to 1:00 PM WHERE: Rudy North Lecture Theatre (CBH 101) in the Centre for Brain Health, UBC Point Grey Campus. Remote attendance by videoconference is possible but you … Read More
![[116] New drug for cystic fibrosis: Regulatory approval, clinical uncertainty?](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2018/12/116-150x150.png)
[116] New drug for cystic fibrosis: Regulatory approval, clinical uncertainty?
A new drug for cystic fibrosis (CF) that combines lumacaftor and ivacaftor (Orkambi), was approved by Health Canada (HC) in 2016 to treat people age 12 and older with the most frequent CF genetic mutation: homozygous F508 deletion of the cystic … Read More
30th Annual Best Science Medicine Course
Friday, May 3, 2019 and Saturday, May 4, 2019 Fairmont Waterfront – 900 Canada Place Way, Vancouver, BC … Read More
![[115] Cannabinoids for Chronic Pain](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2018/11/115-150x150.png)
[115] Cannabinoids for Chronic Pain
Canada's parliament legalized the recreational use of herbal cannabis (marijuana) in October 2018. The well-publicized limitations of clinical research and well-recognized side effects such as cannabis intoxication have not deterred people from … Read More
